Candel Therapeutics, Inc.
CADL
$4.91
-$0.13-2.58%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 30.80% | 56.40% | 55.72% | -5.92% | -45.44% |
| Total Depreciation and Amortization | -14.65% | -6.74% | -1.71% | 0.31% | 3.13% |
| Total Amortization of Deferred Charges | 33.33% | -50.99% | -41.54% | -30.21% | -16.41% |
| Total Other Non-Cash Items | -113.29% | -153.23% | -147.31% | 180.83% | 803.92% |
| Change in Net Operating Assets | 533.82% | -154.92% | 75.64% | -29.51% | 165.90% |
| Cash from Operations | -41.77% | -17.21% | 3.15% | 14.63% | 21.09% |
| Capital Expenditure | -3,568.75% | -201.67% | 77.30% | 96.32% | 96.50% |
| Sale of Property, Plant, and Equipment | -- | 35.00% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -3,400.00% | -285.00% | 74.13% | 96.08% | 94.29% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -27.99% | -49.99% | -139.98% | -499.88% | -- |
| Issuance of Common Stock | -80.11% | 1,172.82% | 2,353.45% | 25,061.41% | -- |
| Repurchase of Common Stock | -- | -472.73% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -40.50% | 4,535.62% | 19,085.24% | 6,907.05% | 78,017.36% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -74.38% | 366.43% | 360.29% | 298.10% | 294.09% |